# Stemson Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stemson-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.stemsontx.com
- Total disclosed funding: $23M
- Latest round: Series A (Jul 17, 2021)
- Investors on record: 5

## About

Stemson Therapeutics, LLC, based in the US, operates as a pre-clinical biotechnology company focused on developing innovative therapies to treat hair loss through advanced regenerative technologies.Founded in 2018 in San Diego, US, Stemson Therapeutics, LLC specializes in the development of therapeutic solutions for hair loss. The company was established by Alexey Terskikh and Geoff Hamilton, with Geoff Hamilton serving as the CEO. Stemson Therapeutics raised USD 15 mn in Series A funding on July 17, 2021, led by Data Collective, with participation from AbbVie Biotech Ventures and Genoa Ventures, marking its second deal to date and bringing the total amount raised to USD 15 mn.Stemson Therapeutics focuses on developing proprietary therapeutic solutions aimed at curing hair loss. Their innovative approach leverages advanced regenerative techniques designed to restore hair growth effectively, catering to a diverse range of patients experiencing hair loss conditions.Stemson Therapeutics generates revenue through strategic partnerships in the biotech sector, engaging with institutional clients and potential commercial distributors. Their business model includes potential revenue from ongoing therapeutic applications as their solutions advance through clinical development.Following the Series A funding round in July 2021, Stemson Therapeutics plans to utilize the USD 15 mn to accelerate the development of their proprietary therapeutic solution for hair loss. The company aims to launch its first therapeutic product by the end of 2023 and expand its market reach within North America and Europe. Additionally, they are exploring collaborations with healthcare providers and research institutions to enhance their product offerings and reach a broader patient demographic.

## Funding rounds

- Series A, Jul 17, 2021, $15M — AbbVie Ventures, DCVC, Genoa Ventures
- Seed, Sep 16, 2020, $7.5M — Allergan Inc, Fortunis Capital

## Investors

- Allergan Inc — Seed
- Fortunis Capital (https://capitalatlas.ai/funds/fortunis-capital) — Seed
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A
- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Series A